-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Residual lesion (MRD) evaluation can help guide the length
MRD status at randomization showed independent prognostic value: median progression-free survival (PFS) in patients with MRD-negative (-) and MRD-positive (+) was 38.
A landmark 14-month analysis showed that patients who switched from MRD+ status to MRD-status had longer PFS compared with patients with persistent MRD+ status (2-year PFS rate: 76.
In patients with MRD+ at randomized grouping, Ixazomib maintenance therapy prolonged PFS compared to placebo (median PFS: 18.
In summary, the findings show that the prognostic value of a single-time point MRD assessment is limited
Original Source:
Bruno Paiva, et al.